Compare Crescent Energy Company Class A Common Stock (CRGY) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crescent Energy Company Class A Common Stock vs Sana Biotechnology Inc — how do they compare? Crescent Energy Company Class A Common Stock trades at $12.7 (market cap $4.30B), while Sana Biotechnology Inc trades at $2.8 (market cap $836.71M). The key difference: Crescent Energy Company Class A Common Stock is far larger — about 5.1× Sana Biotechnology Inc's market cap, and Crescent Energy Company Class A Common Stock pays a 3.69% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crescent Energy Company Class A Common Stock for 1 Days and Sana Biotechnology Inc for 23 Days on average.
| CRGY | SANA | |
|---|---|---|
Market Cap | $4.30B | $836.71M |
Volume | 15,201,625 | 4,507,444 |
Sector | Energy | Health |
52-Week High | $15.37 | $5.92 |
52-Week Low | $7.75 | $2.68 |
Typical Hold Time | 1 Days | 23 Days |
Enterprise Value | $9.31B | $749.96M |
Dividend Yield | 3.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SANA Biotechnology trades at $2.79, up 2.57% today, but faces significant fundamental challenges with no revenue, negative EBITDA of -$192.96M, and deeply negative ROE of -152.87%. Technical indicators show bearish momentum with moving averages signaling sell pressure, though oscillators remain neutral. The company continues to burn cash with -$55.33M net cash flow in 2025, relying on financing activities to fund operations while advancing its cell therapy pipeline through multiple investor presentations.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA represents a high-risk biotech investment with substantial execution risk. The absence of revenue, persistent losses, and cash burn require careful monitoring of clinical milestones. Near-term catalysts depend on pipeline progress, but shareholders face dilution risk from continued financing needs amid challenging technical conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Crescent Energy Company Class A Common Stock
Crescent Energy acquires, develops, and produces oil and natural gas from onshore U.S. basins. Its portfolio includes producing assets with oil and natural gas exposure.
Read more on CRGY →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
